Your browser doesn't support javascript.
loading
Glucose Promotes EMMPRIN/CD147 and the Secretion of Pro-Angiogenic Factors in a Co-Culture System of Endothelial Cells and Monocytes.
Ghandour, Fransis; Kassem, Sameer; Simanovich, Elina; Rahat, Michal A.
Affiliation
  • Ghandour F; Department of Internal Medicine A, Carmel Medical Center, Haifa 3436212, Israel.
  • Kassem S; Department of Internal Medicine A, Carmel Medical Center, Haifa 3436212, Israel.
  • Simanovich E; The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.
  • Rahat MA; Immunotherapy Laboratory, Carmel Medical Center, Haifa 3436212, Israel.
Biomedicines ; 12(4)2024 Mar 22.
Article de En | MEDLINE | ID: mdl-38672062
ABSTRACT
Vascular complications in Type 2 diabetes mellitus (T2DM) patients increase morbidity and mortality. In T2DM, angiogenesis is impaired and can be enhanced or reduced in different tissues ("angiogenic paradox"). The present study aimed to delineate differences between macrovascular and microvascular endothelial cells that might explain this paradox. In a monoculture system of human macrovascular (EaHy926) or microvascular (HMEC-1) endothelial cell lines and a monocytic cell line (U937), high glucose concentrations (25 mmole/L) increased the secretion of the pro-angiogenic factors CD147/EMMPRIN, VEGF, and MMP-9 from both endothelial cells, but not from monocytes. Co-cultures of EaHy926/HMEC-1 with U937 enhanced EMMPRIN and MMP-9 secretion, even in low glucose concentrations (5.5 mmole/L), while in high glucose HMEC-1 co-cultures enhanced all three factors. EMMPRIN mediated these effects, as the addition of anti-EMMPRIN antibody decreased VEGF and MMP-9 secretion, and inhibited the angiogenic potential assessed through the wound assay. Thus, the minor differences between the macrovascular and microvascular endothelial cells cannot explain the angiogenic paradox. Metformin, a widely used drug for the treatment of T2DM, inhibited EMMPRIN, VEGF, and MMP-9 secretion in high glucose concentration, and the AMPK inhibitor dorsomorphin enhanced it. Thus, AMPK regulates EMMPRIN, a key factor in diabetic angiogenesis, suggesting that targeting EMMPRIN may help in the treatment of diabetic vascular complications.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Biomedicines Année: 2024 Type de document: Article Pays d'affiliation: Israël Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Biomedicines Année: 2024 Type de document: Article Pays d'affiliation: Israël Pays de publication: Suisse